Product image
InVivoPlus anti-mouse VISTA
BP0310
ApplicationsFlow Cytometry, Neutralisation/Blocking
Product group Antibodies
ReactivityMouse
Overview
- SupplierBio X Cell
- Product NameInVivoPlus anti-mouse VISTA
- Delivery Days Customer7
- ApplicationsFlow Cytometry, Neutralisation/Blocking
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone ID13F3
- Concentration4-11 mg/ml
- Estimated Purity>95%
- HostHamster
- IsotypeIgG
- Scientific DescriptionThe 13F3 monoclonal antibody reacts with mouse V-domain Ig suppressor of T cell activation (VISTA) also known as PD-1H and B7-H5. VISTA is a 309 aa type I transmembrane glycoprotein and a member of the Ig superfamily. VISTA is expressed on naïve and activated T cells, NK cells, macrophages, dendritic cells, and neutrophils. VISTA functions as a negative immune-checkpoint protein that suppresses T cell cytokine production and proliferation. VISTA is overexpressed by tumor-infiltrating lymphocytes, such as myeloid cells and regulatory T cells. Blockade of VISTA with the 13F3 antibody results in delayed tumor growth in mouse models of melanoma.
- ReactivityMouse
- Storage Instruction2°C to 8°C
- UNSPSC12352203
References
- FOXD3 Regulates VISTA Expression in Melanoma. Rosenbaum SR et al., 2020 Jan 14, Cell RepRead more
- CXCL17 Chemokine-Dependent Mobilization of CXCR8(+)CD8(+) Effector Memory and Tissue-Resident Memory T Cells in the Vaginal Mucosa Is Associated with Protection against Genital Herpes. Srivastava R et al., 2018 Apr 15, J ImmunolRead more
- Blocking the VISTA pathway enhances disease progression in (NZB x NZW) F1 female mice. Sergent PA et al., 2018 Feb, LupusRead more
- VISTA Deficiency Accelerates the Development of Fatal Murine Lupus Nephritis. Ceeraz S et al., 2017 Apr, Arthritis RheumatolRead more
- VISTA Regulates the Development of Protective Antitumor Immunity. Le Mercier I et al., 2014 Apr 1, Cancer ResRead more
- VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. Wang L et al., 2011 Mar 14, J Exp MedRead more